Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Forest Excels: Celexa, Lexapro Help Company In Down Quarter On Wall Street

Executive Summary

Forest Labs is off to a fast start in fourth quarter trading, as the company has found a winning formula during a prolonged down market for brand name pharmaceutical stocks

You may also be interested in...



Schering under SEC investigation

Schering-Plough's handling of an earnings warning issued Oct. 3 has prompted an inquiry by the Securities & Exchange Commission. The company lowered its outlook for the third quarter and warned of an earnings decline in 2003; the company's stock dropped 15% in the two days leading up to the formal announcement (1"The Pink Sheet" Oct. 7, p. 19)...

Schering under SEC investigation

Schering-Plough's handling of an earnings warning issued Oct. 3 has prompted an inquiry by the Securities & Exchange Commission. The company lowered its outlook for the third quarter and warned of an earnings decline in 2003; the company's stock dropped 15% in the two days leading up to the formal announcement (1"The Pink Sheet" Oct. 7, p. 19)...

Premarin/Prempro Rxs Stabilize; Wyeth Predicts $300 Mil. Drop In 2nd Half

Wyeth is seeing some stabilization in the Premarin franchise despite a 40% drop in prescriptions for Prempro and a 15% decline in Premarin scripts since release of the Women's Health Initiative study results

Related Content

UsernamePublicRestriction

Register

PS040577

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel